Amedisys Q4 2023 Adj EPS $0.940 Misses $1.030 Estimate, Sales $570.800M Beat $567.713M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amedisys reported Q4 2023 adjusted EPS of $0.940, missing the $1.030 estimate, but sales of $570.800M exceeded the $567.713M estimate, marking a 1.55% increase from the previous year.
March 05, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amedisys Q4 2023 earnings missed EPS estimates but beat sales forecasts, showing a slight year-over-year growth.
The miss on the EPS estimate could negatively impact investor sentiment towards AMED in the short term, but the beat on sales forecasts and the year-over-year growth might offset some of the negative impact. The mixed results lead to a neutral short-term price direction score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100